Related Experiment Video

Updated: Oct 17, 2025

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
06:03

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

Published on: September 20, 2024

1.5K

Response to COVID-19 mRNA vaccination in multiple myeloma is conserved but impaired compared to controls

Samuel Bitoun1,2, Julien Henry3, Christelle Vauloup-Fellous4

  • 1Rheumatology Department, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, FHU CARE, 78 Avenue du general Leclerc, 94270, Le Kremlin-Bicêtre, France. samuel.bitoun@aphp.fr.

Journal of Hematology & Oncology
|October 14, 2021
PubMed

Insights

Multiple myeloma patients showed a strong response to mRNA COVID-19 vaccines, with 89% achieving humoral immunity. Uncontrolled disease was linked to a lower vaccine response in these high-risk patients.

Area of Science:

  • Immunology
  • Oncology
  • Infectious Diseases

Background:

  • Multiple myeloma patients face a higher risk of severe COVID-19.
  • Previous vaccine responses in these patients were suboptimal.
  • mRNA vaccines offer potential for improved immunogenicity.

Discussion:

  • MM patients exhibited lower Anti-Spike IgG levels post-vaccination compared to controls.
  • Despite this, a significant majority (89%) achieved a humoral response.
  • Neutralizing antibodies were detected in 74% of MM patients versus 96% of controls.

Key Insights:

  • The BNT162b2 mRNA vaccine elicits a substantial immune response in multiple myeloma patients.
  • Uncontrolled disease status emerged as the primary predictor of vaccine non-response.
  • Daratumumab treatment did not abrogate the neutralizing capacity of anti-SARS-CoV-2 antibodies.

Outlook:

  • mRNA vaccines offer significant protection for multiple myeloma patients.
  • Further research should focus on optimizing vaccination strategies for MM patients with active disease.
Keywords:
COVID-19DaratumumabMultiple myelomaNeutralizationSARS-COV-2Vaccine

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.6K
Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-1908:48

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

3.0K

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
562
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
740
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
75.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
25